Pfizer and BioNTech’s Covid-19 and flu vaccine failed to meet a key goal in a late-stage trial, jeopardising a highly anticipated product that would help the drugmakers to compete in the post-Covid jab market.
輝瑞(Pfizer)和BioNTech的新冠/流感疫苗在后期試驗中未能達到一個關鍵目標，這給這款備受期待的產品帶來了風險，該產品將幫助這兩家藥企在后新冠時代疫苗市場競爭。
您已閱讀7%（294字），剩余93%（3687字）包含更多重要信息，訂閱以繼續探索完整內容，并享受更多專屬服務。